Glycated hemoglobin, commonly known as hemoglobin A1c (HbA1c), is a critical biochemical marker used in diabetes mellitus management to monitor long-term glycemic control and evaluate the risk of complications. Studies such as the Diabetes Control and Complications Trial (DCCT) and the United Kingdom Prospective Diabetes Study (UKPDS) have conclusively demonstrated the direct correlation between glycemic control, as measured by HbA1c, and the risk of complications. To ensure adherence to clinical guidelines, diabetes organizations worldwide recommend specific HbA1c targets based on DCCT/UKPDS HbA1c. The National Glycohemoglobin Standardization Program (NGSP) was established to standardize GHB/HbA1c results in clinical laboratories, thereby promoting consistency with DCCT results.
The BioHermes Innovative Lab HbA1c Device A1C EZ 2.0 is a portable handheld hemoglobin A1c device for diabetes management that employs boronate affinity chromatography, a patented technology in numerous…